{
    "clinical_study": {
        "@rank": "45155", 
        "arm_group": {
            "arm_group_label": "MLN4924 and azacitidine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is an open-label, multicenter, phase 1b, dose-escalation study of MLN4924 in\n      combination with azacitidine in adult patients with AML. The patient population will consist\n      of patients 60 years of age or older, previously diagnosed with World Health\n      Organization(WHO)-defined AML, who are unlikely to benefit from standard induction therapy\n      and who have not received definitive treatment for AML or prior treatment with azacitidine\n      or decitabine."
        }, 
        "brief_title": "Study of MLN4924 Plus Azacitidine in Treatment-Na\u00efve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myelogenous Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with WHO-defined AML, 60 years of age or older, who are unlikely to benefit\n             from standard induction therapy, defined as having at least 1 of the following:\n\n               1. Greater than or equal to 75 years of age\n\n               2. Antecedent hematologic disease\n\n               3. Known adverse cytogenetic risk\n\n               4. Eastern Eastern Cooperative Oncology Group (ECOG) PS = 2\n\n          -  Patient must not have received definitive treatment for AML, defined as any prior\n             chemotherapy with antileukemic activity\n\n          -  ECOG PS 0 to 2\n\n          -  Expected survival longer than 3 months from enrollment in the study\n\n          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2\n             effective methods of contraception or agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception or agree to\n             practice true abstinence\n\n          -  Voluntary written consent must be given before performance of any study-related\n             procedure\n\n          -  Suitable venous access for the study-required blood sampling\n\n          -  Adequate clinical laboratory values during the screening period as specified in the\n             protocol\n\n          -  Able to undergo bone marrow aspiration and biopsy at screening\n\n        Exclusion Criteria:\n\n          -  Previous treatment with azacitidine or decitabine\n\n          -  Known favorable cytogenetic risk\n\n          -  Any serious medical or psychiatric illness\n\n          -  Treatment with any investigational products\n\n          -  Known hypersensitivity to azacitidine or mannitol\n\n          -  Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow,\n             by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone\n             marrow, or by other accepted analysis\n\n          -  Active uncontrolled infection or severe infectious disease\n\n          -  Major surgery within 14 days before the first dose of study drug\n\n          -  Life-threatening illness unrelated to cancer\n\n          -  Clinically uncontrolled central nervous system (CNS) involvement\n\n          -  Known human immunodeficiency virus (HIV) positive\n\n          -  Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C\n             infection\n\n          -  Known hepatic cirrhosis or severe pre-existing hepatic impairment\n\n          -  Known cardiac/cardiopulmonary disease\n\n          -  Left ventricular ejection fraction\n\n          -  Known moderate to severe chronic obstructive pulmonary disease, interstitial lung\n             disease, and pulmonary fibrosis\n\n          -  Body mass index > 40 kg/m\u00b2\n\n          -  Treatment with CYP3A inducers within 14 days before the first dose of MLN4924\n\n          -  Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose\n             of study drug, except for hydroxyurea\n\n          -  Patients who are unwilling or unable to refrain from using hydroxymethylglutaryl\n             coenzyme A (HMG CoA) reductase inhibitors (statins) starting 5 days before the\n             initial study drug administration and throughout the study will not be permitted to\n             enroll"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814826", 
            "org_study_id": "C15009"
        }, 
        "intervention": {
            "arm_group_label": "MLN4924 and azacitidine", 
            "description": "MLN4924 (IV) and azacitidine (IV) in AML patients to determine maximum tolerated dose (MTD) on a 28-day cycle:\nAzacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles\nMLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles\nBoth agents given on Days 1, 3, and 5 of Cycle 1 and all subsequent cycles", 
            "intervention_name": "MLN4924 and azacitidine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MLN4924", 
            "Acute", 
            "Myelogenous", 
            "Leukemia"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Juli Murphy"
                }, 
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Blood and Marrow Transplant Program"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Judes Fleurimont"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami School of Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Salah Nabhan"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Na\u00efve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the safety and tolerability of MLN4924 in combination with azacitidine.", 
            "measure": "Number of Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Recorded from the first dose of any study drug through 30 days (+ 10 days) after the last dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic parameters including but not limited to AUC, Cmax, Systemic Clearance, Volume of Distribution, Elimination of Half-Life", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 5 of Cycle 1"
            }, 
            {
                "measure": "Disease response rate", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 22 and assessment of treatment-emergent resistance at Cycle 2 & Cycle 4 any time between Day 20 & Day 28. After Cycle 4, bone marrow assessments will be performed after completion of every third cycle (ie, Cycle 7, Cycle 10, etc.)."
            }, 
            {
                "measure": "Thirty-day mortality rate", 
                "safety_issue": "No", 
                "time_frame": "30 days after the first dose of study drug on Cycle 1"
            }, 
            {
                "measure": "60 Day Mortality Rate", 
                "safety_issue": "No", 
                "time_frame": "60 days after the first dose of study drug on Cycle 1"
            }
        ], 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}